OnCo
drugsProductEstablished

Decipher Prostate

A 22-gene test on the biopsy or surgical specimen that predicts spread and death, used to decide on surveillance or adding hormone therapy.

Validated on NRG/RTOG 9601, 0126, 9902 cohorts; NCCN level-1 evidence; predicts benefit from ADT with radiation in some analyses. Basis of Decipher-stratified trials (NRG GU009/010). Complemented and challenged by ArteraAI Prostate (digital pathology).

Schematic of the modality · Gene-expression genomic classifier · not a molecule; see the RNA sequencing & expression profiling page
Modality
Gene-expression genomic classifier
Mechanism
Whole-transcriptome array; 22-gene random-forest genomic classifier score 0-1.

Trials

top
ClinicalTrials.gov · phase 2/3
refreshed 2026-09-09
5 studies3 recruiting5 Phase 22 Phase 3
Search “Decipher Prostate” on ClinicalTrials.gov →
Counts are from a name search and may include unrelated studies; up to 100 studies are summarised.

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Decipher Prostate
intervention: Decipher Prostate
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Latest papers

top
Literature trend2 papers in the last 12 monthsHow this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"Decipher Prostate" OR ABSTRACT:"Decipher Prostate") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Decipher Prostate, not a curated reading list.

Connected

5top